Johnson & Johnson Ends Phase 2 Study For Dengue Antiviral Amid R&D Reprioritization — Oct 4th, 2024

Johnson & Johnson Ends Phase 2 Study For Dengue Antiviral Amid R&D Reprioritization On Friday, Johnson & Johnson (NYSE:JNJ) announced discontinuing the Phase 2 field study evaluating the efficacy of investigational antiviral candidate mosnodenvir to prevent dengue virus in adults aged 18-...

A look at major attacks in Turkey since 2015 amid deadly Ankara gun assault  — Oct 24th, 2024

Two attackers killed five people and wounded 22 others on Wednesday in a gun attack on the headquarters of Turkey's largest aerospace manufacturer TUSAS that Ankara blamed on the Kurdistan Workers Party (PKK) militant group....

Alumis' Investigational Lead Candidate Supports Superior Profile Than Bristol Myers' Commercialized Drug, Analyst Sees 170% Stock Upside — Oct 17th, 2024

Alumis' Investigational Lead Candidate Supports Superior Profile Than Bristol Myers' Commercialized Drug, Analyst Sees 170% Stock Upside HC Wainwright has initiated coverage on Alumis Inc. (NASDAQ:ALMS), a clinical-stage biopharmaceutical company developing oral therapies for immune-media...

Alumis' Investigational Lead Candidate Supports Superior Profile Than Bristol Myers' Commercialized Drug, Analyst Sees 170% Stock Upside — Oct 17th, 2024

Alumis' Investigational Lead Candidate Supports Superior Profile Than Bristol Myers' Commercialized Drug, Analyst Sees 170% Stock Upside HC Wainwright has initiated coverage on Alumis Inc. (NASDAQ:ALMS), a clinical-stage biopharmaceutical company developing oral therapies for immune-media...

TAK or CTLT: Which Is the Better Value Stock Right Now? — Oct 3rd, 2024

Investors interested in stocks from the Medical - Drugs sector have probably already heard of Takeda Pharmaceutical Co. (TAK) and Catalent (CTLT). But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out. We have found that the best...

Is Takeda Pharmaceutical Co. (TAK) Stock Undervalued Right Now? — Oct 3rd, 2024

Here at Zacks, we focus on our proven ranking system, which places an emphasis on earnings estimates and estimate revisions, to find winning stocks. But we also understand that investors develop their own strategies, so we are constantly looking at the latest trends in value, growth, and m...

A look at major attacks in Turkey since 2015 amid deadly Ankara gun assault  — Oct 24th, 2024

Two attackers killed five people and wounded 22 others on Wednesday in a gun attack on the headquarters of Turkey's largest aerospace manufacturer TUSAS that Ankara blamed on the Kurdistan Workers Party (PKK) militant group....

TAK or CTLT: Which Is the Better Value Stock Right Now? — Oct 3rd, 2024

Investors interested in stocks from the Medical - Drugs sector have probably already heard of Takeda Pharmaceutical Co. (TAK) and Catalent (CTLT). But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out. We have found that the best...

Johnson & Johnson Ends Phase 2 Study For Dengue Antiviral Amid R&D Reprioritization — Oct 4th, 2024

Johnson & Johnson Ends Phase 2 Study For Dengue Antiviral Amid R&D Reprioritization On Friday, Johnson & Johnson (NYSE:JNJ) announced discontinuing the Phase 2 field study evaluating the efficacy of investigational antiviral candidate mosnodenvir to prevent dengue virus in adults aged 18-...

A look at major attacks in Turkey since 2015 amid deadly Ankara gun assault  — Oct 24th, 2024

Two attackers killed five people and wounded 22 others on Wednesday in a gun attack on the headquarters of Turkey's largest aerospace manufacturer TUSAS that Ankara blamed on the Kurdistan Workers Party (PKK) militant group....

Alumis' Investigational Lead Candidate Supports Superior Profile Than Bristol Myers' Commercialized Drug, Analyst Sees 170% Stock Upside — Oct 17th, 2024

Alumis' Investigational Lead Candidate Supports Superior Profile Than Bristol Myers' Commercialized Drug, Analyst Sees 170% Stock Upside HC Wainwright has initiated coverage on Alumis Inc. (NASDAQ:ALMS), a clinical-stage biopharmaceutical company developing oral therapies for immune-media...

A look at major attacks in Turkey since 2015 amid deadly Ankara gun assault  — Oct 24th, 2024

Two attackers killed five people and wounded 22 others on Wednesday in a gun attack on the headquarters of Turkey's largest aerospace manufacturer TUSAS that Ankara blamed on the Kurdistan Workers Party (PKK) militant group....

Is Takeda Pharmaceutical Co. (TAK) Stock Undervalued Right Now? — Oct 3rd, 2024

Here at Zacks, we focus on our proven ranking system, which places an emphasis on earnings estimates and estimate revisions, to find winning stocks. But we also understand that investors develop their own strategies, so we are constantly looking at the latest trends in value, growth, and m...

A look at major attacks in Turkey since 2015 amid deadly Ankara gun assault  — Oct 24th, 2024

Two attackers killed five people and wounded 22 others on Wednesday in a gun attack on the headquarters of Turkey's largest aerospace manufacturer TUSAS that Ankara blamed on the Kurdistan Workers Party (PKK) militant group....

Johnson & Johnson Ends Phase 2 Study For Dengue Antiviral Amid R&D Reprioritization — Oct 4th, 2024

Johnson & Johnson Ends Phase 2 Study For Dengue Antiviral Amid R&D Reprioritization On Friday, Johnson & Johnson (NYSE:JNJ) announced discontinuing the Phase 2 field study evaluating the efficacy of investigational antiviral candidate mosnodenvir to prevent dengue virus in adults aged 18-...

Alumis' Investigational Lead Candidate Supports Superior Profile Than Bristol Myers' Commercialized Drug, Analyst Sees 170% Stock Upside — Oct 17th, 2024

Alumis' Investigational Lead Candidate Supports Superior Profile Than Bristol Myers' Commercialized Drug, Analyst Sees 170% Stock Upside HC Wainwright has initiated coverage on Alumis Inc. (NASDAQ:ALMS), a clinical-stage biopharmaceutical company developing oral therapies for immune-media...

Alumis' Investigational Lead Candidate Supports Superior Profile Than Bristol Myers' Commercialized Drug, Analyst Sees 170% Stock Upside — Oct 17th, 2024

Alumis' Investigational Lead Candidate Supports Superior Profile Than Bristol Myers' Commercialized Drug, Analyst Sees 170% Stock Upside HC Wainwright has initiated coverage on Alumis Inc. (NASDAQ:ALMS), a clinical-stage biopharmaceutical company developing oral therapies for immune-media...

TAK or CTLT: Which Is the Better Value Stock Right Now? — Oct 3rd, 2024

Investors interested in stocks from the Medical - Drugs sector have probably already heard of Takeda Pharmaceutical Co. (TAK) and Catalent (CTLT). But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out. We have found that the best...

A look at major attacks in Turkey since 2015 amid deadly Ankara gun assault  — Oct 24th, 2024

Two attackers killed five people and wounded 22 others on Wednesday in a gun attack on the headquarters of Turkey's largest aerospace manufacturer TUSAS that Ankara blamed on the Kurdistan Workers Party (PKK) militant group....

A look at major attacks in Turkey since 2015 amid deadly Ankara gun assault  — Oct 24th, 2024

Two attackers killed five people and wounded 22 others on Wednesday in a gun attack on the headquarters of Turkey's largest aerospace manufacturer TUSAS that Ankara blamed on the Kurdistan Workers Party (PKK) militant group....

TAK or CTLT: Which Is the Better Value Stock Right Now? — Oct 3rd, 2024

Investors interested in stocks from the Medical - Drugs sector have probably already heard of Takeda Pharmaceutical Co. (TAK) and Catalent (CTLT). But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out. We have found that the best...

Is Takeda Pharmaceutical Co. (TAK) Stock Undervalued Right Now? — Oct 3rd, 2024

Here at Zacks, we focus on our proven ranking system, which places an emphasis on earnings estimates and estimate revisions, to find winning stocks. But we also understand that investors develop their own strategies, so we are constantly looking at the latest trends in value, growth, and m...

TAK or CTLT: Which Is the Better Value Stock Right Now? — Oct 3rd, 2024

Investors interested in stocks from the Medical - Drugs sector have probably already heard of Takeda Pharmaceutical Co. (TAK) and Catalent (CTLT). But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out. We have found that the best...

Alumis' Investigational Lead Candidate Supports Superior Profile Than Bristol Myers' Commercialized Drug, Analyst Sees 170% Stock Upside — Oct 17th, 2024

Alumis' Investigational Lead Candidate Supports Superior Profile Than Bristol Myers' Commercialized Drug, Analyst Sees 170% Stock Upside HC Wainwright has initiated coverage on Alumis Inc. (NASDAQ:ALMS), a clinical-stage biopharmaceutical company developing oral therapies for immune-media...

TAK or CTLT: Which Is the Better Value Stock Right Now? — Oct 3rd, 2024

Investors interested in stocks from the Medical - Drugs sector have probably already heard of Takeda Pharmaceutical Co. (TAK) and Catalent (CTLT). But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out. We have found that the best...

A look at major attacks in Turkey since 2015 amid deadly Ankara gun assault  — Oct 24th, 2024

Two attackers killed five people and wounded 22 others on Wednesday in a gun attack on the headquarters of Turkey's largest aerospace manufacturer TUSAS that Ankara blamed on the Kurdistan Workers Party (PKK) militant group....

Johnson & Johnson Ends Phase 2 Study For Dengue Antiviral Amid R&D Reprioritization — Oct 4th, 2024

Johnson & Johnson Ends Phase 2 Study For Dengue Antiviral Amid R&D Reprioritization On Friday, Johnson & Johnson (NYSE:JNJ) announced discontinuing the Phase 2 field study evaluating the efficacy of investigational antiviral candidate mosnodenvir to prevent dengue virus in adults aged 18-...

A look at major attacks in Turkey since 2015 amid deadly Ankara gun assault  — Oct 24th, 2024

Two attackers killed five people and wounded 22 others on Wednesday in a gun attack on the headquarters of Turkey's largest aerospace manufacturer TUSAS that Ankara blamed on the Kurdistan Workers Party (PKK) militant group....

Is Takeda Pharmaceutical Co. (TAK) Stock Undervalued Right Now? — Oct 3rd, 2024

Here at Zacks, we focus on our proven ranking system, which places an emphasis on earnings estimates and estimate revisions, to find winning stocks. But we also understand that investors develop their own strategies, so we are constantly looking at the latest trends in value, growth, and m...

Johnson & Johnson Ends Phase 2 Study For Dengue Antiviral Amid R&D Reprioritization — Oct 4th, 2024

Johnson & Johnson Ends Phase 2 Study For Dengue Antiviral Amid R&D Reprioritization On Friday, Johnson & Johnson (NYSE:JNJ) announced discontinuing the Phase 2 field study evaluating the efficacy of investigational antiviral candidate mosnodenvir to prevent dengue virus in adults aged 18-...

Johnson & Johnson Ends Phase 2 Study For Dengue Antiviral Amid R&D Reprioritization — Oct 4th, 2024

Johnson & Johnson Ends Phase 2 Study For Dengue Antiviral Amid R&D Reprioritization On Friday, Johnson & Johnson (NYSE:JNJ) announced discontinuing the Phase 2 field study evaluating the efficacy of investigational antiviral candidate mosnodenvir to prevent dengue virus in adults aged 18-...

Alumis' Investigational Lead Candidate Supports Superior Profile Than Bristol Myers' Commercialized Drug, Analyst Sees 170% Stock Upside — Oct 17th, 2024

Alumis' Investigational Lead Candidate Supports Superior Profile Than Bristol Myers' Commercialized Drug, Analyst Sees 170% Stock Upside HC Wainwright has initiated coverage on Alumis Inc. (NASDAQ:ALMS), a clinical-stage biopharmaceutical company developing oral therapies for immune-media...

Is Takeda Pharmaceutical Co. (TAK) Stock Undervalued Right Now? — Oct 3rd, 2024

Here at Zacks, we focus on our proven ranking system, which places an emphasis on earnings estimates and estimate revisions, to find winning stocks. But we also understand that investors develop their own strategies, so we are constantly looking at the latest trends in value, growth, and m...

A look at major attacks in Turkey since 2015 amid deadly Ankara gun assault  — Oct 24th, 2024

Two attackers killed five people and wounded 22 others on Wednesday in a gun attack on the headquarters of Turkey's largest aerospace manufacturer TUSAS that Ankara blamed on the Kurdistan Workers Party (PKK) militant group....

TAK or CTLT: Which Is the Better Value Stock Right Now? — Oct 3rd, 2024

Investors interested in stocks from the Medical - Drugs sector have probably already heard of Takeda Pharmaceutical Co. (TAK) and Catalent (CTLT). But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out. We have found that the best...

A look at major attacks in Turkey since 2015 amid deadly Ankara gun assault  — Oct 24th, 2024

Two attackers killed five people and wounded 22 others on Wednesday in a gun attack on the headquarters of Turkey's largest aerospace manufacturer TUSAS that Ankara blamed on the Kurdistan Workers Party (PKK) militant group....

Is Takeda Pharmaceutical Co. (TAK) Stock Undervalued Right Now? — Oct 3rd, 2024

Here at Zacks, we focus on our proven ranking system, which places an emphasis on earnings estimates and estimate revisions, to find winning stocks. But we also understand that investors develop their own strategies, so we are constantly looking at the latest trends in value, growth, and m...

A look at major attacks in Turkey since 2015 amid deadly Ankara gun assault  — Oct 24th, 2024

Two attackers killed five people and wounded 22 others on Wednesday in a gun attack on the headquarters of Turkey's largest aerospace manufacturer TUSAS that Ankara blamed on the Kurdistan Workers Party (PKK) militant group....

Is Takeda Pharmaceutical Co. (TAK) Stock Undervalued Right Now? — Oct 3rd, 2024

Here at Zacks, we focus on our proven ranking system, which places an emphasis on earnings estimates and estimate revisions, to find winning stocks. But we also understand that investors develop their own strategies, so we are constantly looking at the latest trends in value, growth, and m...

Is Takeda Pharmaceutical Co. (TAK) Stock Undervalued Right Now? — Oct 3rd, 2024

Here at Zacks, we focus on our proven ranking system, which places an emphasis on earnings estimates and estimate revisions, to find winning stocks. But we also understand that investors develop their own strategies, so we are constantly looking at the latest trends in value, growth, and m...

Is Takeda Pharmaceutical Co. (TAK) Stock Undervalued Right Now? — Oct 3rd, 2024

Here at Zacks, we focus on our proven ranking system, which places an emphasis on earnings estimates and estimate revisions, to find winning stocks. But we also understand that investors develop their own strategies, so we are constantly looking at the latest trends in value, growth, and m...

Alumis' Investigational Lead Candidate Supports Superior Profile Than Bristol Myers' Commercialized Drug, Analyst Sees 170% Stock Upside — Oct 17th, 2024

Alumis' Investigational Lead Candidate Supports Superior Profile Than Bristol Myers' Commercialized Drug, Analyst Sees 170% Stock Upside HC Wainwright has initiated coverage on Alumis Inc. (NASDAQ:ALMS), a clinical-stage biopharmaceutical company developing oral therapies for immune-media...

TAK or CTLT: Which Is the Better Value Stock Right Now? — Oct 3rd, 2024

Investors interested in stocks from the Medical - Drugs sector have probably already heard of Takeda Pharmaceutical Co. (TAK) and Catalent (CTLT). But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out. We have found that the best...

Johnson & Johnson Ends Phase 2 Study For Dengue Antiviral Amid R&D Reprioritization — Oct 4th, 2024

Johnson & Johnson Ends Phase 2 Study For Dengue Antiviral Amid R&D Reprioritization On Friday, Johnson & Johnson (NYSE:JNJ) announced discontinuing the Phase 2 field study evaluating the efficacy of investigational antiviral candidate mosnodenvir to prevent dengue virus in adults aged 18-...

TAK or CTLT: Which Is the Better Value Stock Right Now? — Oct 3rd, 2024

Investors interested in stocks from the Medical - Drugs sector have probably already heard of Takeda Pharmaceutical Co. (TAK) and Catalent (CTLT). But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out. We have found that the best...

A look at major attacks in Turkey since 2015 amid deadly Ankara gun assault  — Oct 24th, 2024

Two attackers killed five people and wounded 22 others on Wednesday in a gun attack on the headquarters of Turkey's largest aerospace manufacturer TUSAS that Ankara blamed on the Kurdistan Workers Party (PKK) militant group....

Alumis' Investigational Lead Candidate Supports Superior Profile Than Bristol Myers' Commercialized Drug, Analyst Sees 170% Stock Upside — Oct 17th, 2024

Alumis' Investigational Lead Candidate Supports Superior Profile Than Bristol Myers' Commercialized Drug, Analyst Sees 170% Stock Upside HC Wainwright has initiated coverage on Alumis Inc. (NASDAQ:ALMS), a clinical-stage biopharmaceutical company developing oral therapies for immune-media...

Johnson & Johnson Ends Phase 2 Study For Dengue Antiviral Amid R&D Reprioritization — Oct 4th, 2024

Johnson & Johnson Ends Phase 2 Study For Dengue Antiviral Amid R&D Reprioritization On Friday, Johnson & Johnson (NYSE:JNJ) announced discontinuing the Phase 2 field study evaluating the efficacy of investigational antiviral candidate mosnodenvir to prevent dengue virus in adults aged 18-...

Johnson & Johnson Ends Phase 2 Study For Dengue Antiviral Amid R&D Reprioritization — Oct 4th, 2024

Johnson & Johnson Ends Phase 2 Study For Dengue Antiviral Amid R&D Reprioritization On Friday, Johnson & Johnson (NYSE:JNJ) announced discontinuing the Phase 2 field study evaluating the efficacy of investigational antiviral candidate mosnodenvir to prevent dengue virus in adults aged 18-...

A look at major attacks in Turkey since 2015 amid deadly Ankara gun assault  — Oct 24th, 2024

Two attackers killed five people and wounded 22 others on Wednesday in a gun attack on the headquarters of Turkey's largest aerospace manufacturer TUSAS that Ankara blamed on the Kurdistan Workers Party (PKK) militant group....